Analyst Research

Report Title Price
Provider: Reuters Investment Profile
Provider: GlobalData
Provider: GlobalData

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Biomerieux SA issues FY 2014 sales guidance and confirms FY 2013 operating income guidance; announces exclusive agreement with Gilead Sciences Inc

Wednesday, 22 Jan 2014 01:00am EST 

Biomerieux SA:Sees sales growth of between 3 percent and 5 percent in FY 2014.Confirms operating income before non-recurring items target for FY 2013.Says it signed an exclusive agreement with Gilead Sciences Inc, a biopharmaceutical company focusing on therapeutics for unmet medical needs, to co-develop an assay that may be a potential companion diagnostic of a Gilead drug candidate.FY 2013 sales 1,588 million euros.FY 2014 revenue 1,700 million euros-Thomson Reuters I/B/E/S Estimates. 

Company Quote

0.43 +0.56%
23 Jul 2014